Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

180.13
Delayed Data
As of 4:00pm ET
 -3.05 / -1.67%
Today’s Change
128.58
Today|||52-Week Range
184.00
+33.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$10.0B

Company Description

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Dublin, Ireland.

Contact Information

Jazz Pharmaceuticals Plc
Waterloo Exchange
Dublin Dublin 4
P:(531) 634-7800
Investor Relations:
(531) 634-7892

Employees

Shareholders

Mutual fund holders59.80%
Other institutional32.71%
Individual stakeholders18.23%

Top Executives

Bruce C. CozaddChairman & Chief Executive Officer
Daniel N. SwisherPresident & Chief Operating Officer
Matthew P. YoungChief Financial Officer & Executive Vice President
Paul TreacySenior Vice President-Technical Operations
Robert McKagueChief Compliance Officer & Senior Vice President